CGEM - Cullinan Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$31.00
DETAILS
HIGH:
$37.00
LOW:
$28.00
MEDIAN:
$30.00
CONSENSUS:
$31.00
UPSIDE:
123.99%
About Cullinan Therapeutics, Inc. (https://cullinantherapeutics.com)
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Nadim Ahmed | President, Chief Executive Officer & Director | 1968 | $1,168,266 USD |
| Jeffrey Jones | Chief Medical Officer | 1971 | $801,783 USD |
| Mary Kay Fenton | Chief Financial Officer | 1964 | $768,257 USD |
| Patrick A. Baeuerle | Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board | 1958 | $763,734 USD |
| Corinne Savill | Chief Business Officer | 1959 | – |
| Jacquelyn L. Sumer | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | 1978 | – |
| Jennifer Michaelson | Chief Scientific Officer | 1967 | – |
| Kevin A. Johnston | Chief Technical Operations Officer | – | – |
| Nicholas Smith | Head of Investor Relations | – | – |
| Rose Weldon | Senior Vice President of Corporate Affairs | – | – |
| Steve Andre | Chief Human Resources Officer | – | – |